Pfizer plans to pull leukemia drug Mylotarg from U.S. market

06/21/2010 | Reuters

Pfizer will voluntarily take Mylotarg off the U.S. market Oct. 15 after the injectable drug failed to show efficacy during a study when given in combination with chemotherapy to patients with acute myeloid leukemia. The decision follows the FDA's recommendation to withdraw the product because of safety concerns and lack of clinical benefit.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ